Welcome to our dedicated page for Hikma Pharmaceuticals Plc news (Ticker: HKMPY), a resource for investors and traders seeking the latest updates and insights on Hikma Pharmaceuticals Plc stock.
Hikma Pharmaceuticals PLC (HKMPY) generates a steady flow of news related to its role as a multinational pharmaceutical company focused on branded and non-branded generic medicines, sterile injectables and complex technologies such as nasal sprays. The company’s announcements highlight new product launches, regulatory milestones, manufacturing investments and strategic partnerships across North America, the Middle East and North Africa (MENA), and Europe.
Recent news has included US Food and Drug Administration (FDA) approvals and launches of hospital-focused therapies such as TYZAVAN (vancomycin injection, USP), a ready-to-use or ready-to-infuse glycopeptide antibacterial indicated for septicemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections in appropriate adult and pediatric patients. Hikma has also announced the US launch of COMBOGESIC IV (acetaminophen and ibuprofen) injection, an opioid-free intravenous pain management option for adults where IV administration is clinically necessary.
Other updates cover Hikma’s role in addressing the opioid overdose crisis through KLOXXADO (naloxone HCl) nasal spray 8 mg, including a shelf-life extension and an exclusive commercial partnership with Emergent BioSolutions for sales in the US and Canada. Oncology and biosimilar developments feature in news about the FDA approval of STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing Stelara, under a commercialization agreement with Bio-Thera Solutions, and the acquisition of an FDA-approved ANDA for trametinib tablets from Novugen.
Investors and healthcare professionals following HKMPY news can also expect coverage of Hikma’s manufacturing and R&D investments in the US, partnerships to expand access to next-generation sequencing cancer diagnostics in MENA, and venture-backed digital health initiatives through Hikma Ventures. This news page provides a centralized view of these developments, helping readers understand how Hikma’s product pipeline, partnerships and regional activities are evolving over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hikma Pharmaceuticals and Glenmark Specialty announced the US launch of RYALTRIS™, a nasal spray for treating seasonal allergic rhinitis (SAR), approved by the FDA for patients aged 12 and older. This combination therapy relieves nasal and ocular symptoms, offering onset relief in 15 minutes. With 60 million Americans affected by allergic rhinitis, this product addresses a significant unmet need, particularly as many patients report inadequate symptom control. Hikma aims to expand its specialty business in the US through this launch, utilizing its existing salesforce to reach healthcare providers.
Hikma Pharmaceuticals PLC has publicly clarified that it has not engaged in any transaction with Opiant Pharmaceuticals, directly contradicting a prior announcement from PR Newswire. The earlier communication suggested Hikma entered into a commercialization and licensing agreement for OPNT003, Nasal Nalmefene, in Europe and the UK, which Hikma has confirmed is not the case. This statement helps to prevent any potential misinterpretations regarding Hikma's current partnerships and licensing activities.
Hikma Pharmaceuticals has completed its acquisition of Custopharm for an initial $375 million, enhancing its US Injectables portfolio significantly. This acquisition adds 13 approved products and strengthens Hikma's R&D capabilities, bolstering its position as the second-largest supplier of generic sterile injectables in the US. Notable achievements include Custopharm's strong regulatory track record with four first-to-market FDA approvals. The acquisition was approved by the US Federal Trade Commission and positions Hikma for better service delivery to healthcare providers and patients.
Hikma Pharmaceuticals PLC announced that it has received preliminary approval from the US Federal Trade Commission (FTC) for its acquisition of Custopharm Inc. from Water Street Healthcare Partners. This follows the initial announcement made on September 27, 2021. With all necessary regulatory approvals now obtained, Hikma is moving forward to close the transaction and will provide further updates upon completion.
Hikma Pharmaceuticals announced a $15 million investment from its venture capital arm, Hikma Ventures, in Activ Surgical, enhancing the Series B financing to a total of $60 million. Activ Surgical is developing AI-driven surgical technologies aimed at improving surgical outcomes. The ActivSight imaging module, which enhances visualization during surgery, has received FDA clearance and is set for broader availability in 2022. This investment will facilitate Activ Surgical's global launch, empowering surgeons with advanced decision-making tools and improving patient safety.
Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, has led an $11 million financing round for NuvoAir, a digital health company focusing on chronic disease management and decentralized clinical trials, particularly for respiratory conditions like COPD and asthma. This investment extends NuvoAir's Series A funding to $25 million in total. The funds will be used to enhance NuvoAir's platform, grow its team, and expand clinical services globally.